TY - JOUR
T1 - The bidirectional longitudinal association between depressive symptoms and HbA1c
T2 - A systematic review and meta-analysis
AU - Beran, Magdalena
AU - Muzambi, Rutendo
AU - Geraets, Anouk
AU - Albertorio-Diaz, Juan Rafael
AU - Adriaanse, Marcel C.
AU - Iversen, Marjolein M.
AU - Kokoszka, Andrzej
AU - Nefs, Giesje
AU - Nouwen, Arie
AU - Pouwer, Frans
AU - Huber, J. rg W.
AU - Schmitt, Andreas
AU - European Depression in Diabetes (EDID) Research Consortium
AU - Schram, Miranda T.
AU - for the European Depression in Diabetes (EDID) Research Consortium
N1 - Funding Information: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors thank Wolfgang Viechtbauer, Associate Professor at the Department of Psychiatry and Neuropsychology at Maastricht University, for his contribution in finding a suitable method to transform regression coefficients for the random-effects pooling in our meta-analysis. Publisher Copyright: © 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Aim: To investigate whether there is a bidirectional longitudinal association of depression with HbA1c. Methods: We conducted a systematic literature search in PubMed, PsycINFO, CINAHL and EMBASE for observational, longitudinal studies published from January 2000 to September 2020, assessing the association between depression and HbA1c in adults. We assessed study quality with the Newcastle-Ottawa-Scale. Pooled effect estimates were reported as partial correlation coefficients (rp) or odds ratios (OR). Results: We retrieved 1642 studies; 26 studies were included in the systematic review and eleven in the meta-analysis. Most studies (16/26) focused on type 2 diabetes. Study quality was rated as good (n = 19), fair (n = 2) and poor (n = 5). Of the meta-analysed studies, six investigated the longitudinal association between self-reported depressive symptoms and HbA1c and five the reverse longitudinal association, with a combined sample size of n = 48,793 and a mean follow-up of 2 years. Higher levels of baseline depressive symptoms were associated with subsequent higher levels of HbA1c (partial r = 0.07; [95% CI 0.03, 0.12]; I238%). Higher baseline HbA1c values were also associated with 18% increased risk of (probable) depression (OR = 1.18; [95% CI 1.12,1.25]; I20.0%). Conclusions: Our findings support a bidirectional longitudinal association between depressive symptoms and HbA1c. However, the observed effect sizes were small and future research in large-scale longitudinal studies is needed to confirm this association. Future studies should investigate the role of type of diabetes and depression, diabetes distress and diabetes self-management behaviours. Our results may have clinical implications, as depressive symptoms and HbA1c levels could be targeted concurrently in the prevention and treatment of diabetes and depression. Registration: PROSPERO ID CRD42019147551.
AB - Aim: To investigate whether there is a bidirectional longitudinal association of depression with HbA1c. Methods: We conducted a systematic literature search in PubMed, PsycINFO, CINAHL and EMBASE for observational, longitudinal studies published from January 2000 to September 2020, assessing the association between depression and HbA1c in adults. We assessed study quality with the Newcastle-Ottawa-Scale. Pooled effect estimates were reported as partial correlation coefficients (rp) or odds ratios (OR). Results: We retrieved 1642 studies; 26 studies were included in the systematic review and eleven in the meta-analysis. Most studies (16/26) focused on type 2 diabetes. Study quality was rated as good (n = 19), fair (n = 2) and poor (n = 5). Of the meta-analysed studies, six investigated the longitudinal association between self-reported depressive symptoms and HbA1c and five the reverse longitudinal association, with a combined sample size of n = 48,793 and a mean follow-up of 2 years. Higher levels of baseline depressive symptoms were associated with subsequent higher levels of HbA1c (partial r = 0.07; [95% CI 0.03, 0.12]; I238%). Higher baseline HbA1c values were also associated with 18% increased risk of (probable) depression (OR = 1.18; [95% CI 1.12,1.25]; I20.0%). Conclusions: Our findings support a bidirectional longitudinal association between depressive symptoms and HbA1c. However, the observed effect sizes were small and future research in large-scale longitudinal studies is needed to confirm this association. Future studies should investigate the role of type of diabetes and depression, diabetes distress and diabetes self-management behaviours. Our results may have clinical implications, as depressive symptoms and HbA1c levels could be targeted concurrently in the prevention and treatment of diabetes and depression. Registration: PROSPERO ID CRD42019147551.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85114299515&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34407250
UR - http://www.scopus.com/inward/record.url?scp=85114299515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114299515&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/dme.14671
DO - https://doi.org/10.1111/dme.14671
M3 - Review article
C2 - 34407250
SN - 0742-3071
VL - 39
SP - 1
EP - 11
JO - Diabetic medicine
JF - Diabetic medicine
IS - 2
M1 - e14671
ER -